Life Technologies Extends Partnership with DNAVEC, Launches Next Generation Stem Cell Reprogramming Solution

- R&D collaborative agreement aims to further develop Sendai virus-based tools for basic and translational research

CARLSBAD, Calif., Oct. 22, 2013 /PRNewswire/ -- Life Technologies Corporation( http://www.lifetechnologies.com/us/en/home.html ) has extended its collaborative agreement with Japanese firm DNAVEC Corporation to launch CytoTune(TM)-iPS 2.0 Sendai Reprogramming Kit( http://www.lifetechnologies.com/order/catalog/product/A16517?ICID=search-product ), the next-generation research technology that enables the most efficient method to develop induced pluripotent stem (iPS) cells from human somatic cells. The newest kit doubles the number of colonies that can be produced and represents the latest in a series of products that are planned from the collaboration.

CytoTune(TM)-iPS 2.0 Sendai Reprogramming Kit uses a benign RNA virus developed by DNAVEC to deliver the reprogramming factors and clears out of the cell after about five replication cycles. The technology helps overcome major hurdles associated with traditional reprogramming techniques, which are highly inefficient and can lead to unwanted genetic mutations since vectors must insert themselves in the host cell's DNA to deliver their payload.

By extending its collaborative research agreement with DNAVEC Corp., Life Technologies plans to build on the success it's forged through the broad adoption of the CytoTune(TM) technology. Under the agreement, DNAVEC will undertake early stage R&D to apply its Sendai virus technology to third- and fourth-generation tools for use within the reprogramming and stem-cell workflows.

"This technology will provide revolutionary new tools to cell engineering research worldwide,"said Mamoru Hasegawa, Ph.D., President of DNAVEC. "We are excited about the initiation of a new collaborative development program with Life Technologies, which aims to develop new vectors and products."

Efficient development of iPS cells provides highly sought-after advantages for the basic and translational research fields. Scientists who test existing or novel drugs in the hopes of treating specific conditions can have faster access to patient-derived, physiologically accurate cells for disease modeling studies.

"This partnership enables both organizations to leverage their respective strengths," said Chris Armstrong, Ph.D., General Manager and Vice President of Primary and Stem Cell Systems at Life Technologies. "DNAVEC's deep expertise in Sendai virus technology to develop breakthrough solutions is complemented by Life Technologies' global distribution channels that can rapidly put these novel products in the hands of customers to accelerate research and the promise of stem cells."

CytoTune(TM)-iPS 2.0 Sendai Reprogramming Kit is for Research Use Only; not intended for diagnostic purposes.

About Life Technologies

Life Technologies Corporation( http://www.lifetechnologies.com/us/en/home.html?cid=fl-home%3fCID=fl-home ) (NASDAQ: LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions are secured by more than 5,000 patents and licenses that span the entire biological spectrum -- scientific exploration, molecular diagnostics, 21stcentury forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.

Life Technologies' Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

(Logo: http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)

Life Technologies Media Contact:

Atsuko Igawa

Tel: +81-36832-9446

atsuko.igawa@lifetech.com( mailto:atsuko.igawa@lifetech.com )

SOURCE Life Technologies Corporation